Posters presented by Investigators:
Basic Studies
Clinical
Basic Studies
| D'ISA Raffaele | Italy |
Electrophysiological and behavioural impairments in the cuprizone demyelination/remyelination mouse model - ID78
|
| HOBART Jeremy | United Kingdom |
A new patient-reported outcome (PRO) walking scale for Multiple Sclerosis clinical trials - ID88
|
| HOBART Jeremy |
United Kingdom |
Measuring Upper Limb Function (ULF) in MS Clinical Trials: Definition, Conceptualisation, Measurement - ID89
|
| LARONI Alice | Italy |
Systematic mapping of global family-orientated educational offerings for people with multiple sclerosis and members of their support networks - ID74
|
| NIKOLAIDIS Ioannis | Greece |
Humoral immunity following neural precursor cell administration in naive rodents - ID13
|
| RIECKMANN Peter | Germany |
Long-Term Efficacy Including Clinical NEDA and Safety of Three-Times-Weekly Dosing Regimen Of Glatiramer Acetate: 7-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study - ID33
|
| TIENARI Pentti | Finland |
Somatic mutations in CD8+ cells in multiple sclerosis patients and controls - ID52
|
| CENTONZE Diego | Italy |
PEG-IFN BETA-1A PRE-FILLED PEN (PLEGRIDY®) improves satisfaction in patients with relapsing-remitting multiple sclerosis who were dissatisfied with other subcutaneous interferons (platinum study) - ID37
|
| D'HAESELEER Miguel | Belgium |
Feasibility of internet-based teleconsultation in patients with multiple sclerosis: a pilot study - ID75
|
| COREY Ford | United States | Twenty-Seven Years Of Continuous Treatment Of Multiple Sclerosis With Glatiramer Acetate: Long-Term Efficacy Results of the US Open-Label Extension Study - ID34 View poster - Abstract |
| HARRIS Sarah | United States |
Use of epigenetic cell counting to determine the effect of ozanimod on circulating leukocyte subtypes in patients with relapsing multiple sclerosis - ID57
|
| MONTALBAN Xavier | Spain |
Effect of evobrutinib, a Bruton’s tyrosine kinase inhibitor, on immune cell and immunoglobulin levels over 48 weeks in a phase 2 study in relapsing multiple sclerosis - ID32
|
| SEJBAEK Tobias | Denmark |
Neurofilament light chain and levels of fatigue are reduced by dimethyl fumarate – fatigue is not related to neuroaxonal damage - ID97
|
| STEINMAN Lawrence | United States |
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study - ID56
|
Investigations
| ALOISI Francesca | Italy | Cytotoxic CD8 T cells (the effectors) against EBV-infected B cells (the targets): clues for virus-driven immunopathology in multiple sclerosis - ID29 View poster - Abstract |
| HUANG Su-Chun | Italy | Patterns of Neurodegeneration in Macula Differs in Multiple Sclerosis Subtypes: a Voxel-Based Morphometry Study with Optical Coherence Tomography - ID70 View poster - Abstract - Poster presentation recording |
| MESSINA Silvia | United Kngdom | Lesions distribution and normal appearing white matter in demyelinating diseases - ID86 View poster - Abstract |
| YOO Ronnie | United States | Updated incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time - ID84 View poster - Abstract |
Treatment
| COOK Stuart | United States |
Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-Approval Data - ID41
|
| FREEDMAN Mark | Canada |
Efficacy of subcutaneous interferon β-1a in patients with a first clinical demyelinating event: the REbif FLEXible dosing in early multiple sclerosis (REFLEX) study – outcomes in patients stratified by the 2017 McDonald criteria - ID39
|
| GIOVANNONI Gavin | United Kingdom |
Increase of naïve B cells M2 macrophages and reduction of memory B/T cells during immune repopulation at 96 weeks in CLARITY assessed by immune cell deconvolution - ID44
|
| GIOVANNONI Gavin | United Kingdom |
Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies - ID45
|
| HAUSER Stephen | United States |
Exposure-Response Analyses of Ocrelizumab in Patients With Multiple Sclerosis - ID93
|
| HULST Hanneke | The Netherlands | Cladribine decreases CD95 expressing CD4+ and CD8+ cells in lymphoid organs in naïve marmosets (Callithrix jacchus) - ID47 |
| KAP Yolanda | The Netherlands | No Correlation Between Lymphocyte Pharmacodynamics and Autoimmune Adverse Events Following Alemtuzumab Treatment in Patients With Relapsing-Remitting Multiple Sclerosis - ID43 View poster - Abstract |
| KUHLE Jens | Switzerland | Effect of Interferon β-1a Treatment on Serum Neurofilament Light Chain Levels in Patients with a First Clinical Demyelinating Event in the REFLEX trial - ID40 View poster - Abstract |
| LEE Lily | United States | Characterizing the positive experience reported by natalizumab-treated patients with relapsing multiple sclerosis - ID55 View poster - Abstract - Poster presentation recording |
| RIECKMANN Peter | Germany | Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis - ID62 View poster - Abstract |
